DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets
- PMID: 34057732
- DOI: 10.1007/s13402-021-00613-0
DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets
Abstract
Background: The aggressive, invasive and treatment resistant nature of glioblastoma makes it one of the most lethal cancers in humans. Total surgical resection is difficult, and a combination of radiation and chemotherapy is used to treat the remaining invasive cells beyond the tumour border by inducing DNA damage and activating cell death pathways in glioblastoma cells. Unfortunately, recurrence is common and a major hurdle in treatment, often met with a more aggressive and treatment resistant tumour. A mechanism of resistance is the response of DNA repair pathways upon treatment-induced DNA damage, which enact cell-cycle arrest and repair of DNA damage that would otherwise cause cell death in tumour cells.
Conclusions: In this review, we discuss the significance of DNA repair mechanisms in tumour formation, aggression and treatment resistance. We identify an underlying trend in the literature, wherein alterations in DNA repair pathways facilitate glioma progression, while established high-grade gliomas benefit from constitutively active DNA repair pathways in the repair of treatment-induced DNA damage. We also consider the clinical feasibility of inhibiting DNA repair in glioblastoma and current strategies of using DNA repair inhibitors as agents in combination with chemotherapy, radiation or immunotherapy. Finally, the importance of blood-brain barrier penetrance when designing novel small-molecule inhibitors is discussed.
Keywords: Blood-brain barrier; DNA damage response, DNA repair; Glioblastoma; PIKK inhibitor; Treatment resistance.
© 2021. Crown.
Similar articles
-
Estrogen receptor beta enhances chemotherapy response of GBM cells by down regulating DNA damage response pathways.Sci Rep. 2019 Apr 16;9(1):6124. doi: 10.1038/s41598-019-42313-8. Sci Rep. 2019. PMID: 30992459 Free PMC article.
-
Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition.J R Soc Interface. 2020 Jan;17(162):20190722. doi: 10.1098/rsif.2019.0722. Epub 2020 Jan 22. J R Soc Interface. 2020. PMID: 31964274 Free PMC article.
-
Poly(ADP-ribose) polymerase inhibitor increases growth inhibition and reduces G(2)/M cell accumulation induced by temozolomide in malignant glioma cells.Glia. 2002 Oct;40(1):44-54. doi: 10.1002/glia.10113. Glia. 2002. PMID: 12237842
-
DNA repair mechanisms and their clinical impact in glioblastoma.Mutat Res Rev Mutat Res. 2016 Jul-Sep;769:19-35. doi: 10.1016/j.mrrev.2016.05.005. Epub 2016 Jun 21. Mutat Res Rev Mutat Res. 2016. PMID: 27543314 Review.
-
Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors.Anticancer Agents Med Chem. 2010 Sep;10(7):520-33. doi: 10.2174/187152010793498627. Anticancer Agents Med Chem. 2010. PMID: 20879987 Review.
Cited by
-
Oncolytic viral vectors in the era of diversified cancer therapy: from preclinical to clinical.Clin Transl Oncol. 2022 Sep;24(9):1682-1701. doi: 10.1007/s12094-022-02830-x. Epub 2022 May 25. Clin Transl Oncol. 2022. PMID: 35612653 Free PMC article. Review.
-
Integrative analysis of therapy resistance and transcriptomic profiling data in glioblastoma cells identifies sensitization vulnerabilities for combined modality radiochemotherapy.Radiat Oncol. 2022 Apr 19;17(1):79. doi: 10.1186/s13014-022-02052-z. Radiat Oncol. 2022. PMID: 35440003 Free PMC article.
-
Expression Profile, Molecular Association, and Clinical Significance of POLD4 in Glioblastoma.Cell Mol Neurobiol. 2023 Oct;43(7):3753-3765. doi: 10.1007/s10571-023-01393-x. Epub 2023 Aug 6. Cell Mol Neurobiol. 2023. PMID: 37543966 Free PMC article.
-
Filamentous Bacteriophage-A Powerful Carrier for Glioma Therapy.Front Immunol. 2021 Sep 10;12:729336. doi: 10.3389/fimmu.2021.729336. eCollection 2021. Front Immunol. 2021. PMID: 34566987 Free PMC article. Review.
-
STAT3-mediated upregulation of LINC00520 contributed to temozolomide chemoresistance in glioblastoma by interacting with RNA-binding protein LIN28B.Cancer Cell Int. 2022 Aug 9;22(1):248. doi: 10.1186/s12935-022-02659-y. Cancer Cell Int. 2022. PMID: 35945579 Free PMC article.
References
-
- Q.T. Ostrom, H. Gittleman, P. Farah, A. Ondracek, Y. Chen, Y. Wolinsky, N.E. Stroup, C. Kruchko, J.S. Barnholtz-Sloan, CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006–2010. Neuro. Oncol. (2013). https://doi.org/10.1093/neuonc/not151 - DOI - PubMed - PMC
-
- D.N. Louis, A. Perry, G. Reifenberger, A. von Deimling, D. Figarella–Branger, W.K. Cavenee, H. Ohgaki, O.D. Wiestler, P. Kleihues, D.W. Ellison, The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131, 803–820 (2016)
-
- M.T.C. Poon, C.L.M. Sudlow, J.D. Figueroa, P.M. Brennan, Longer-term (≥ 2 years) survival in patients with glioblastoma in population-based studies pre- and post-2005: a systematic review and meta-analysis. Sci. Rep. (2020). https://doi.org/10.1038/s41598-020-68011-4 - DOI - PubMed - PMC
-
- M. Koshy, B.J. Mccarthy, Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J. Neuroncol. 107, 207–212 (2014) - DOI
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous